Pfizer Inc. $PFE Shares Bought by Te Ahumairangi Investment Management Ltd

Key Points

• Te Ahumairangi Investment Management Ltd increased its holdings in Pfizer Inc. by 7.5%, acquiring an additional 14,973 shares, which brings their total to 214,396 shares valued at $5.43 million.
• Pfizer reported $0.78 earnings per share for the last quarter, surpassing the consensus estimate of $0.58, and had revenue of $14.65 billion, beating expectations of $13.43 billion.
• The company recently announced a quarterly dividend of $0.43 per share, translating to an annualized dividend of $1.72 and a yield of 7.0%.

Te Ahumairangi Investment Management Ltd lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 7.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 214,396 shares of the biopharmaceutical company's stock after acquiring an additional 14,973 shares during the period. Pfizer makes up 1.1% of Te Ahumairangi Investment Management Ltd's portfolio, making the stock its 29th biggest position. Te Ahumairangi Investment Management Ltd's holdings in Pfizer were worth $5,433,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. WPG Advisers LLC acquired a new stake in shares of Pfizer in the first quarter worth $35,000. Trexquant Investment LP increased its position in shares of Pfizer by 137.3% in the first quarter. Trexquant Investment LP now owns 1,817,207 shares of the biopharmaceutical company's stock worth $46,048,000 after acquiring an additional 1,051,471 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management increased its position in shares of Pfizer by 4.8% in the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 21,623 shares of the biopharmaceutical company's stock worth $548,000 after acquiring an additional 987 shares in the last quarter. Huber Capital Management LLC increased its position in shares of Pfizer by 17.4% in the first quarter. Huber Capital Management LLC now owns 573,288 shares of the biopharmaceutical company's stock worth $14,527,000 after acquiring an additional 85,000 shares in the last quarter. Finally, Landscape Capital Management L.L.C. grew its holdings in Pfizer by 38.7% during the 1st quarter. Landscape Capital Management L.L.C. now owns 41,077 shares of the biopharmaceutical company's stock valued at $1,041,000 after purchasing an additional 11,469 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Shares of PFE stock opened at $24.60 on Friday. The firm has a market cap of $139.86 billion, a P/E ratio of 13.09, a P/E/G ratio of 0.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The firm has a fifty day moving average of $24.78 and a two-hundred day moving average of $24.39.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

A number of research firms recently weighed in on PFE. Morgan Stanley raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Berenberg Bank lowered their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Jefferies Financial Group raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.